Serum Institute of India (SII) in order to produce 2 billion doses of Covid-19 vaccines.In August, Novavax signed a deal with Pune-based Serum Institute to produce a minimum of one billion doses of its vaccine candidate for low-and middle-income countries and India.However, as a part of the expanded agreement, Serum Institute will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate.“Today’s agreement with Serum Institute enhances Novavax’ commitment to equitable global delivery of our COVID-19 vaccine.
With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on.